| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2022-02-11 | New Leaf Biopharma Opportunities I, L.P. | Addex Therapeutics Ltd. | 2,366,293 | 4.5% | EDGAR |
| SC 13D/A | 2022-01-10 | Growth Equity Opportunities Fund IV, LLC | Addex Therapeutics Ltd. | 7,704,600 | 20.4% | EDGAR |
| SC 13D/A | 2021-09-08 | Dyer Timothy Mark | Addex Therapeutics Ltd. | 3,630,988 | 9.7% | EDGAR |
| SC 13G | 2021-02-16 | CAXTON CORP | Addex Therapeutics Ltd. | 2,316,293 | 8.4% | EDGAR |
| SC 13G | 2021-02-12 | CREDIT SUISSE AG/ | Addex Therapeutics Ltd. | 1,874,245 | 571.0% | EDGAR |
| SC 13G | 2021-02-10 | New Leaf Biopharma Opportunities I, L.P. | Addex Therapeutics Ltd. | 2,316,293 | 7.1% | EDGAR |
| SC 13D | 2021-01-22 | Growth Equity Opportunities Fund IV, LLC | Addex Therapeutics Ltd. | 7,704,600 | 21.5% | EDGAR |
| SC 13D | 2020-11-03 | Dyer Timothy Mark | Addex Therapeutics Ltd. | 2,867,549 | 8.7% | EDGAR |